Intervention not reported
Mortality, due to pneumonia · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in mortality, due to pneumonia (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse events (all) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse events (all) (high certainty).
1 finding from 1 review
Intervention not reported
All pneumonia events · patients with chronic obstructive pulmonary disease
The intervention probably leads to higher all pneumonia events (moderate certainty).
1 finding from 1 review
Intervention not reported
Withdrawals · patients with chronic obstructive pulmonary disease
The intervention leads to lower withdrawals (high certainty).
1 finding from 1 review
Intervention not reported
Outcomes · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐fatal, serious adverse pneumonia events (requiring hospital admission) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse pneumonia events (requiring hospital… (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in mortality (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
Six‐minute walk distance · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes hospital admissions due to exacerbations compared with tiotropium (very low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty).
1 finding from 1 review
Exacerbations requiring steroids, antibiotics or both · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in exacerbations requiring steroids, antibiotics or both compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide leads to higher quality of life Number of patients who achieved at least 4 units… compared with placebo (high certainty).
1 finding from 1 review
Six‐minute walk distance · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide leads to lower hospital admissions due to exacerbations compared with placebo (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Exacerbations requiring steroids, antibiotics or both · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes exacerbations requiring steroids, antibiotics or both compared with tiotropium (very low certainty).
1 finding from 1 review
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
All‐cause mortality · patients with managing pulmonary tuberculosis
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
Intervention not reported
Sputum Conversion by 2 months · patients with managing pulmonary tuberculosis
The intervention may leads to higher sputum Conversion by 2 months (low certainty).
1 finding from 1 review